Annual CFO
-$96.77 M
-$20.39 M-26.70%
December 31, 2024
Summary
- As of March 12, 2025, URGN annual cash flow from operations is -$96.77 million, with the most recent change of -$20.39 million (-26.70%) on December 31, 2024.
- During the last 3 years, URGN annual CFO has fallen by -$11.87 million (-13.99%).
- URGN annual CFO is now -2410.00% below its all-time high of $4.19 million, reached on December 31, 2016.
Performance
URGN Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$13.62 M
+$14.04 M+50.77%
December 1, 2024
Summary
- As of March 12, 2025, URGN quarterly cash flow from operations is -$13.62 million, with the most recent change of +$14.04 million (+50.77%) on December 1, 2024.
- Over the past year, URGN quarterly CFO has increased by +$14.04 million (+50.77%).
- URGN quarterly CFO is now -624.41% below its all-time high of $2.60 million, reached on September 30, 2017.
Performance
URGN Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$96.77 M
-$623.00 K-0.65%
December 1, 2024
Summary
- As of March 12, 2025, URGN TTM cash flow from operations is -$96.77 million, with the most recent change of -$623.00 thousand (-0.65%) on December 1, 2024.
- Over the past year, URGN TTM CFO has dropped by -$623.00 thousand (-0.65%).
- URGN TTM CFO is now -3425.17% below its all-time high of -$2.75 million, reached on March 31, 2017.
Performance
URGN TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
URGN Cash From Operations Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -26.7% | +50.8% | -0.7% |
3 y3 years | -14.0% | +32.1% | -14.0% |
5 y5 years | -36.3% | +47.6% | -36.3% |
URGN Cash From Operations Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -26.7% | at low | -4.8% | +57.1% | -26.7% | at low |
5 y | 5-year | -36.3% | +8.6% | -4.8% | +61.8% | -36.3% | +12.5% |
alltime | all time | -2410.0% | +8.6% | -624.4% | +61.8% | -3425.2% | +12.5% |
UroGen Pharma Cash From Operations History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2024 | -$96.77 M(+26.7%) | - | - |
Dec 2024 | - | -$13.62 M(-50.8%) | -$96.77 M(+0.6%) |
Sep 2024 | - | -$27.66 M(+16.5%) | -$96.14 M(+12.1%) |
Jun 2024 | - | -$23.75 M(-25.2%) | -$85.78 M(+4.2%) |
Mar 2024 | - | -$31.73 M(+144.2%) | -$82.30 M(+7.8%) |
Dec 2023 | -$76.38 M(-12.8%) | -$13.00 M(-24.9%) | -$76.38 M(-10.3%) |
Sep 2023 | - | -$17.30 M(-14.7%) | -$85.13 M(-0.4%) |
Jun 2023 | - | -$20.27 M(-21.4%) | -$85.44 M(-4.4%) |
Mar 2023 | - | -$25.81 M(+18.6%) | -$89.37 M(+2.1%) |
Dec 2022 | -$87.56 M(+3.1%) | -$21.75 M(+23.5%) | -$87.56 M(+2.0%) |
Sep 2022 | - | -$17.61 M(-27.2%) | -$85.88 M(-1.0%) |
Jun 2022 | - | -$24.20 M(+0.8%) | -$86.74 M(+6.4%) |
Mar 2022 | - | -$24.00 M(+19.6%) | -$81.49 M(-4.0%) |
Dec 2021 | -$84.89 M(-19.8%) | -$20.07 M(+8.6%) | -$84.89 M(-1.4%) |
Sep 2021 | - | -$18.48 M(-2.5%) | -$86.06 M(-7.1%) |
Jun 2021 | - | -$18.95 M(-30.9%) | -$92.67 M(-5.1%) |
Mar 2021 | - | -$27.40 M(+29.0%) | -$97.65 M(-7.8%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2020 | -$105.89 M(+49.1%) | -$21.24 M(-15.3%) | -$105.89 M(-4.3%) |
Sep 2020 | - | -$25.08 M(+4.8%) | -$110.64 M(+12.8%) |
Jun 2020 | - | -$23.93 M(-32.8%) | -$98.09 M(+10.6%) |
Mar 2020 | - | -$35.63 M(+37.1%) | -$88.72 M(+24.9%) |
Dec 2019 | -$71.02 M(+90.2%) | -$26.00 M(+107.5%) | -$71.02 M(+28.4%) |
Sep 2019 | - | -$12.53 M(-13.9%) | -$55.30 M(+6.2%) |
Jun 2019 | - | -$14.55 M(-18.8%) | -$52.05 M(+14.0%) |
Mar 2019 | - | -$17.93 M(+74.4%) | -$45.64 M(+22.3%) |
Dec 2018 | -$37.33 M(+290.2%) | -$10.28 M(+10.8%) | -$37.33 M(+13.1%) |
Sep 2018 | - | -$9.28 M(+13.9%) | -$33.01 M(+56.2%) |
Jun 2018 | - | -$8.15 M(-15.3%) | -$21.13 M(+28.5%) |
Mar 2018 | - | -$9.62 M(+61.5%) | -$16.45 M(+71.9%) |
Dec 2017 | -$9.57 M(-328.4%) | -$5.96 M(-329.5%) | -$9.57 M(+165.1%) |
Sep 2017 | - | $2.60 M(-175.0%) | -$3.61 M(-41.8%) |
Jun 2017 | - | -$3.46 M(+26.1%) | -$6.21 M(+126.1%) |
Mar 2017 | - | -$2.75 M | -$2.75 M |
Dec 2016 | $4.19 M(-158.4%) | - | - |
Dec 2015 | -$7.17 M | - | - |
FAQ
- What is UroGen Pharma annual cash flow from operations?
- What is the all time high annual CFO for UroGen Pharma?
- What is UroGen Pharma annual CFO year-on-year change?
- What is UroGen Pharma quarterly cash flow from operations?
- What is the all time high quarterly CFO for UroGen Pharma?
- What is UroGen Pharma quarterly CFO year-on-year change?
- What is UroGen Pharma TTM cash flow from operations?
- What is the all time high TTM CFO for UroGen Pharma?
- What is UroGen Pharma TTM CFO year-on-year change?
What is UroGen Pharma annual cash flow from operations?
The current annual CFO of URGN is -$96.77 M
What is the all time high annual CFO for UroGen Pharma?
UroGen Pharma all-time high annual cash flow from operations is $4.19 M
What is UroGen Pharma annual CFO year-on-year change?
Over the past year, URGN annual cash flow from operations has changed by -$20.39 M (-26.70%)
What is UroGen Pharma quarterly cash flow from operations?
The current quarterly CFO of URGN is -$13.62 M
What is the all time high quarterly CFO for UroGen Pharma?
UroGen Pharma all-time high quarterly cash flow from operations is $2.60 M
What is UroGen Pharma quarterly CFO year-on-year change?
Over the past year, URGN quarterly cash flow from operations has changed by +$14.04 M (+50.77%)
What is UroGen Pharma TTM cash flow from operations?
The current TTM CFO of URGN is -$96.77 M
What is the all time high TTM CFO for UroGen Pharma?
UroGen Pharma all-time high TTM cash flow from operations is -$2.75 M
What is UroGen Pharma TTM CFO year-on-year change?
Over the past year, URGN TTM cash flow from operations has changed by -$623.00 K (-0.65%)